Long acting GLP-1 receptor agonist (injectable)
Liraglutide maximum tolerated dose injection once daily
LIRA_SC_MTD_0p3-0p6-0p9-1p2-1p8-2p4-3p0_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 0.51 (0.00 to 39.43) | 0.64 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 6.25 (0.43 to 191) | 0.25 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 7.92 (0.63 to 222) | 0.35 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 2.64 (0.09 to 100) | 0.36 |